Sprint Bioscience Strengthens Its Cancer Metabolism Portfolio

Released on: October 08, 2012, 10:21 am
Industry: Biotech, Pharmaceuticals, Healthcare

-- /EPR NETWORK/ -- Sprint Bioscience, a Swedish company developing oncology therapeutics targeting cancer metabolism, announced today that it has raised money to strengthen its drug discovery portfolio.

The investment by Första Entreprenörsfonden and Almi Invest will enable the company to continue to build a pipeline of drug discovery projects within cancer metabolism.

“We are investing in Sprint Bioscience because we consider their entrepreneurial drive and their particular skills in drug development to be key success factors for the changing environment of the future pharmaceutical industry. Sprint Bioscience’s business strategy involves out-licensing or collaborating at an early stage of drug discovery to ensure that projects are developed with a focus on current and relevant market needs,” says Rune Nordlander, partner at Första Entreprenörsfonden.

Sprint Bioscience is a company founded by experienced drug hunters with an ambition to improve the drug discovery process. "We believe in small organisations with effective working procedures and collaborations throughout the sector," says the company's CEO and co-founder, Dr. Anders Åberg.

"Sprint Bioscience has developed an efficient, fragment-based drug discovery (FBDD) platform that can take parallel projects from initial idea to active molecules tested in cell-based systems in a very short time" Anders Åberg continues. Our goal is to align the early phase in the laboratory with pharmaceutical companies' needs.

Targeting the metabolism in tumours provides exciting opportunities to develop drug therapies with novel mechanisms of action. This could be used to overcome the resistance that many cancer cells develop to current treatments.


For further information, please contact:

Anne-Marie Wenthzel, Director Business Development, Sprint Bioscience AB
Tel: +46-8-411 44 55
Cell Phone: +46-739 399 330
E-mail: amw@sprintbioscience.com

Anders Åberg, CEO and co-founder, Sprint Bioscience AB
Tel: +46-8-411 44 55
Cell Phone: +46-762 738 777
E-mail: anders.aberg@sprintbioscience.com

Contact Details: Sprint Bioscience
Teknikringen 38A
S-114 28 Stockholm
Tel: +46 (0)8-411 44 55


Back to previous page
Home page
Submit your press release